Itepekimab proof-of-concept study in adults with non-cystic fibrosis bronchiectasis

Randomised, double-blind trial in bronchiectasis comparing Itepekimab every 2 weeks, Itepekimab every 4 weeks with alternating placebo and Placebo every 2 weeks (3 arms). Primary endpoint: Annualized rate of moderate or severe pulmonary exacerbations over the treatment period. Started May 2024; status: active, not recruiting.